HER-2/neu and TOPIIα expression in gastric cancer reflect disease severity

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1290-1293

  Liu, Hong Qi ^a   Zhang, Shao Lan ^b   Song, Shu ^a  

^a Yancheng First People's Hospital   (China)

^b Yancheng Health Vocational and Technical College   (China)

Author keywords

Clinicopathological parameter; Gastric cancer; Her 2 neu; Immunohistochemistry; TopoII

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME; AGED; CHEMISTRY; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STOMACH; STOMACH TUMOR;

ADULT; AGED; ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SEVERITY OF ILLNESS INDEX; STOMACH; STOMACH NEOPLASMS;

EID: 84861396274     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11844     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277-300.
2. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003; 362(9380):305-315.
3. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12(1):17-20.
4. Casaretto L, Sousa PL, Mari JJ: Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res 2006; 39 (4):431-440.
5. Kono K, Takahashi A, Ichihara f, et al.: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002; 62(20):5813-5817.
6. Chen B, Luo RC, Cui f, et al.: Association of HER-2/neu expression with prognosis of gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao 2006; 26(3):344-347.
7. Gutierrez C, Schiff R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011; 135(1):55-62.
8. Lottner C, Schwarz S, Diermeier S, et al.: Simultaneous detection of HER2/neu gene amplification and protein over expression in paraffin-embedded breast cancer. J Pathol 2005; 205(5):577-584.
9. Chekerov R, Koensgen D, Klaman I, et al.: Tumor-and stromal cell-specific expression of topoisomerase IIα and HER-2/ neu in primary and recurrent ovarian cancer: Results of a prospective study. Mol Med Report 2009; 2(6):1011-1016.
10. Wang Y, Zhang X: The clinical significance of Her-2/Neu in lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24(12):750-752.
11. Yang fD, Jia ZL: Expression of topoisomerase II alpha in human colorectal carcinoma and its significance. Nanfang Yike Daxue Xuebao 2010; 30(8):1959-1961.
12. Hajduk M, Olszewski WP, Smietana A: Evaluation of the predictive value of topoisomerase II alpha in patients with breast carcinoma. Pol J Pathol 2009; 60(3):115-123.
13. Baiocchi GL, Villanacci V, Rossi E, et al.: HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma. Dig Dis Sci 2009; 54(9):2049-2051.
14. Zini N, Santi S, Ognibene A, et al.: Disrete localization of different DNA topoisomerases in Hela and K562 cell nuclei and sub-nuclear fraction. Exp Cell Res 1994; 210(2):336-348.
15. Adachi N, Miyaike M, Kato S, et al.: Cellular distribution of mammalian DNA topoisomerase is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res 1997; 25(15):3135-3142.
16. Ohashi S, Okamura S, Urano f, et al.: Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer. Gastric Cancer 2007; 10(4):241-250.
17. Amodio R, Zarcone M, Cusimano R, et al.: Target therapy in HER2-overexpressing breast cancer patients. OMICS 2011; 15(6):363-367.
18. Wu W, Ou J, Huang Z, et al.: Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors. Eur J Med Chem 2011; 46(8):3339-3347.
19. Rath-Wolfson L, Hammel I, Kugel V, et al.: Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder. Anal Quant Cytol Histol 2004; 26(4):181-186.
20. Liming S, Yuan Z, Qinghua D, et al.: Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer. Hepato-gastroenterol 2010; 58(106):359-363.
21. Wang G, Huang H, Gao J, et al.: Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenic and prognostic implications. Cancer Genomics Proteomics 2011; 8(3):127-133.
22. Kanta S, Yamane T, Dobashi Y, et al.: Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 2006; 37(10):1333-1343.